NCT00266331

Brief Summary

This study is for the patient with breast cancer. To take part in this study, external beam radiation therapy needs to be part of the treatment plan. Reduced glutathione, an ingredient of RayGel™, has been helpful in decreasing some radiation therapy side effects to the skin. Reduced glutathione plays a vital role in both making DNA and cell repair. This study will measure if RayGel decreases skin reaction in breast cancer patients treated with external beam radiation therapy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P75+ for phase_2 breast-cancer

Timeline
Completed

Started Oct 2004

Typical duration for phase_2 breast-cancer

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2004

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

December 14, 2005

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 16, 2005

Completed
5.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2011

Completed
Last Updated

August 28, 2013

Status Verified

August 1, 2013

Enrollment Period

6.6 years

First QC Date

December 14, 2005

Last Update Submit

August 27, 2013

Conditions

Keywords

Breast cancerRadiation skin protection

Outcome Measures

Primary Outcomes (1)

  • Reduction in skin damage

    Skin reaction scale along with evaluation by radiation oncologist at weekly intervals from start of radiation therapy until completion of radiation.

    Start of radiation therapy until completion

Study Arms (2)

Group A, RayGel Topical Cream

ACTIVE COMPARATOR

RayGel Topical Cream applied in thin layer to the area exposed to radiation 60-90 minutes prior to radiotherapy, standard skin care between treatments.

Drug: Reduced glutathione

Arm B Placebo Topical Cream

PLACEBO COMPARATOR

Placebo Topical Cream applied in thin layer to the area exposed to radiation 60-90 minutes prior to radiotherapy, standard skin care between treatments.

Interventions

Group A, RayGel Topical Cream

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • \. Breast Cancer
  • Radiation

You may not qualify if:

  • Post Mastectomy
  • Previous irradiation of the same breast
  • Pregnacy
  • Younger than 18 years of age

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Legacy Health System

Portland, Oregon, 97210, United States

Location

Related Publications (1)

  • Miko Enomoto T, Johnson T, Peterson N, Homer L, Walts D, Johnson N. Combination glutathione and anthocyanins as an alternative for skin care during external-beam radiation. Am J Surg. 2005 May;189(5):627-30; discussion 630-1. doi: 10.1016/j.amjsurg.2005.02.001.

Related Links

MeSH Terms

Conditions

Breast Neoplasms

Interventions

Glutathione

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

OligopeptidesPeptidesAmino Acids, Peptides, and Proteins

Study Officials

  • Thomas Johnson, MD

    Legacy Health System

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

December 14, 2005

First Posted

December 16, 2005

Study Start

October 1, 2004

Primary Completion

May 1, 2011

Study Completion

May 1, 2011

Last Updated

August 28, 2013

Record last verified: 2013-08

Locations